Beneficial effects of bempedoic acid treatment in polycystic kidney disease cells and mice.
Kenneth R Hallows, Hui Li, Biagio Saitta...
https://pubmed.ncbi.nlm.nih.gov/36504724/Actively Recruiting
Led by Kenneth Hallows · Updated on 2026-09-29
120
Participants Needed
3
Research Sites
26 weeks
Total Duration
Autosomal dominant polycystic kidney disease ADPKD is the most common inherited kidney disease, causing cysts that impair kidney function and often lead to end-stage kidney disease by age 60. Current treatment options are limited, with Tolvaptan being the only FDA-approved drug, but it has side effects like frequent urination, thirst, and possible liver injury. Researchers are studying bempedoic acid BA, a drug approved for high cholesterol, which may target key cellular processes involved in ADPKD and help slow disease progression. This phase 2 clinical trial will randomly assign 120 adults aged 18 to 60 with rapidly progressing ADPKD to receive either bempedoic acid 180 mg daily or a placebo for two years. Participants may be on or off a stable dose of Tolvaptan. The study will be conducted at three specialized centers, with patients monitored regularly through lab tests, questionnaires, and MRI scans to measure kidney and liver volumes and fat content. Researchers will also explore urinary biomarkers related to disease severity and response to treatment. Participants will have in-person visits at baseline, 3, 6, 12, 18, and 24 months to collect urine samples, complete quality of life surveys, and undergo lab tests. MRI scans will be performed at the start, one year, and two years to assess organ volumes. Safety and tolerability will be closely monitored through adverse event tracking and pill counts. The study aims to evaluate if bempedoic acid is safe and tolerable and to gather early data on its effects on kidney function and quality of life over the two-year treatment period.
CONDITIONS
Bempedoic Acid Therapy for Polycystic Kidney Disease
C
Charalett Diggs, RN, MSN
K
Kenneth R Hallows, MD, PhD, FASN
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Kenneth Hallows
Lead Sponsor
University of Maryland, Baltimore County
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Bempedoic acid | Placebo | Tolvaptan (current approved therapy) |
|---|---|---|---|
| What it is | A daily oral investigational drug (bempedoic acid 180 mg) tested in ADPKD patients for safety, tolerability and preliminary efficacy over 24 months | A matching oral placebo pill taken once daily as the trial’s control | An FDA‑approved vasopressin V2 receptor antagonist used to slow kidney function decline in rapidly progressing ADPKD |
| Role in trial | Investigational treatment arm | Placebo control arm | Current standard therapy for rapidly progressing ADPKD, not included in this trial |
| Primary use | To test safety, tolerability and preliminary efficacy for slowing disease progression | To serve as control for assessing investigational treatment effects | To slow decline in kidney function for eligible patients with ADPKD |
| How it is given or performed | Orally once daily as a 180 mg over‑encapsulated tablet | Orally once daily matching over‑encapsulated placebo pill | Orally in dosed regimen titrated by clinical guidelines |
| Evidence supporting use | Preclinical cell and animal studies show reduced kidney growth and metabolic benefit; clinical evidence pending | Not expected to alter disease; serves as control | Clinical trials and guidelines support slowing of kidney function decline in rapidly progressing ADPKD |
| Important known or potential risks | Unknown in ADPKD; safety under investigation over 24 months; risks may mirror those seen in cholesterol trials | No active drug‑related risks | Associated with frequent urination, thirst and liver injury in some patients |
| Key limitations | So far only tested in preclinical models; human effectiveness and safety in ADPKD remain unproven | No therapeutic effect by design | Benefits are modest; side effects and liver monitoring needs limit use |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 24 months
Participants take either bempedoic acid 180 mg daily or a placebo pill for two years while being monitored for safety and effects on kidney disease.
Visits at baseline, 2 weeks, 6 weeks, 3 months, then every 3 months up to 24 months
Duration - 24 months (concurrent with treatment)
Participants complete MRI scans and quality of life surveys at regular intervals to assess kidney and liver volumes and symptoms during treatment.
MRI scans at 0, 12, and 24 months; surveys at baseline, 3, 6, 12, 18, and 24 months
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kenneth R Hallows, Hui Li, Biagio Saitta...
https://pubmed.ncbi.nlm.nih.gov/36504724/Kenneth Hallows
Lead Sponsor
University of Maryland, Baltimore County
Collaborating Sponsor